Product Reports Resources Pricing Login Book a demo

Pandion Therapeutics

Biotech & Life Sciences · Cambridge, United States · Founded 2016 · IPO 2020

Pandion Therapeutics is a biotechnology company focused on developing innovative treatments for autoimmune and inflammatory diseases. The company operates in the biopharmaceutical market, serving patients and healthcare providers. Pandion's business model revolves around its proprietary TALON (Therapeutic Autoimmune reguLatOry proteiN) drug design platform, which allows for the creation of modular precision medicine therapeutics. These therapeutics are engineered to achieve lasting therapeutic outcomes by selectively modulating the immune system. The company generates revenue through the development and potential commercialization of its drug candidates, as well as through partnerships and collaborations with other pharmaceutical companies. Keywords: biotechnology, autoimmune, inflammatory, TALON, precision medicine, immunomodulatory, therapeutics, drug development, healthcare, biopharmaceutical.

Valuation $1–2.5B
Revenue $1–10M
Total funding $100–500M
Power Law Unicorn$1–10B valuation tier

Investors

11 investors on Pandion Therapeutics's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 8 investors entered at this stage
Polaris Partners
Roche Venture Fund
Versant Ventures
SR One
BioInnovation
Boxer Capital
Access Biotechnology
RA Capital Management
Series B+ 3 investors entered at this stage
Boxer Capital
Access Biotechnology
RA Capital Management

Global footprint

Where Pandion Therapeutics has talent and traffic

Workforce by country
🇺🇸 United States · Cambridge HQ
Book a demo for the full country breakdown

Talent graph

The shape of Pandion Therapeutics's talent

Dealroom maps Pandion Therapeutics's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

4 team members profilednamed & role-tagged by Dealroom
4 executives & foundersidentified by name
DimensionScore
AI Talent Score hidden — book a demo
Engineering Score hidden — book a demo
Product Score hidden — book a demo
Go-to-market Score hidden — book a demo
Leadership Score hidden — book a demo
Research Score hidden — book a demo
Book a demo to unlock Pandion Therapeutics's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Patent intelligence

$8M patent portfolio · 16 active families

Estimated portfolio value
$8M
0.41% of market cap · 2.8× smaller than top peer Relay Therapeutics ($21M)
16 active patent families
Where Pandion Therapeutics innovates BiochemistryDermatomalImmune privilegeImmunologic ToleranceImmunology

Where Pandion Therapeutics concentrates vs peers

Each axis is a top-10 topic across Pandion Therapeutics and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Pandion Therapeutics

An AI-synthesized read of the highest-engagement posts about Pandion Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Pandion Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles